<DOC>
	<DOCNO>NCT02186821</DOCNO>
	<brief_summary>The purpose signal seek study determine whether treatment ceritinib demonstrate sufficient efficacy select pathway-activated solid tumor and/or hematologic malignancy warrant study .</brief_summary>
	<brief_title>Ceritinib ( LDK378 ) Patients Whose Tumors Have Aberrations ALK ROS1 ( SIGNATURE )</brief_title>
	<detailed_description />
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Patient confirm diagnosis select solid tumor ( except ALK+ NSCLC ) hematological malignancy need treatment radiologic progression relapse . Patient must preidentified tumor ALK ROS1 positive mutation , translocation , rearrangement amplification . The qualify alteration must assess report CLIAcertified laboratory . ALK positivity assess IHC FISH allow . Patient must receive least one prior treatment recurrent , metastatic and/or locally advanced disease standard therapy option anticipate result durable remission . Patient progressive measurable disease per RECIST 1.1 appropriate hematological guideline . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . Patient receive prior treatment ceritinib . Patients symptomatic CNS metastasis neurologically unstable require increase dos steroid within 2 week prior study entry manage CNS symptom . Patient receive chemotherapy anticancer therapy ≤ 4 week ( 6 week nitrosourea , monoclonal antibody mitomycinC ) prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hematological malignancy</keyword>
	<keyword>solid tumor malignancy</keyword>
	<keyword>mutation</keyword>
	<keyword>translocation</keyword>
	<keyword>rearrangement</keyword>
	<keyword>amplification</keyword>
	<keyword>ALK</keyword>
	<keyword>ROS1</keyword>
	<keyword>NSCLC</keyword>
	<keyword>B-cell lymphoma</keyword>
</DOC>